A detailed history of Ifp Advisors, Inc transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Ifp Advisors, Inc holds 144 shares of IRWD stock, worth $640. This represents 0.0% of its overall portfolio holdings.

Number of Shares
144
Holding current value
$640
% of portfolio
0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$5.58 - $8.61 $803 - $1,239
144 New
144 $0
Q3 2023

Oct 12, 2023

BUY
$8.25 - $11.35 $3,753 - $5,164
455 New
455 $4,000
Q4 2022

Feb 07, 2023

BUY
$9.9 - $12.43 $79 - $99
8 Added 0.4%
2,013 $38,000
Q3 2022

Nov 08, 2022

SELL
$10.14 - $12.38 $212 - $259
-21 Reduced 1.04%
2,005 $38,000
Q2 2022

Sep 06, 2022

BUY
$11.05 - $12.72 $22,387 - $25,770
2,026 New
2,026 $38,000
Q2 2022

Aug 12, 2022

SELL
$11.05 - $12.72 $22,387 - $25,770
-2,026 Closed
0 $0
Q1 2022

Sep 06, 2022

BUY
$10.61 - $12.88 $21,495 - $26,094
2,026 New
2,026 $25,000
Q3 2021

Oct 06, 2021

SELL
$11.92 - $13.92 $0 - $0
0 Closed
0 $0
Q2 2021

Jul 13, 2021

BUY
$10.16 - $13.11 $0 - $0
0 New
0 $0
Q1 2021

Apr 30, 2021

BUY
$9.04 - $11.86 $0 - $0
0 New
0 $0
Q4 2020

Jan 25, 2021

SELL
$9.05 - $12.2 $1,267 - $1,708
-140 Closed
0 $0
Q1 2020

May 12, 2020

BUY
$8.58 - $14.01 $1,201 - $1,961
140 New
140 $1,000
Q4 2019

Jan 17, 2020

BUY
$8.22 - $14.0 $0 - $0
0 New
0 $0
Q3 2019

Nov 07, 2019

BUY
$8.59 - $10.96 $0 - $0
0 New
0 $0
Q4 2018

Jan 23, 2019

SELL
$7.8 - $16.13 $382 - $790
-49 Closed
0 $0
Q3 2018

Oct 25, 2018

SELL
$14.31 - $17.65 $171 - $211
-12 Reduced 19.67%
49 $0
Q2 2018

Aug 07, 2018

BUY
$11.83 - $16.2 $721 - $988
61 New
61 $0
Q3 2017

Oct 30, 2017

SELL
$12.07 - $14.87 $796 - $981
-66 Closed
0 $0
Q2 2017

Jun 03, 2019

BUY
N/A
66
66 $1,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $682M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Ifp Advisors, Inc Portfolio

Follow Ifp Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ifp Advisors, Inc with notifications on news.